Federal Agency Session
-
Register
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
Federal Agency Session
Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
On-Demand Session
Overview
During this 1-hour, on-demand session from the 2024 ASAM State of the Art Course, federal agency leaders from NIAAA, SAMHSA, and NIDA give brief overviews about emerging issues and advances in addiction medicine from their respective organizations. Following the presentations, ASAM President, Dr. Brian Hurley, leads the agencies in a lively discussion about the most pressing topics in addiction medicine.
These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:
- Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
- Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
- Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine
This conference addresses all 6 ACGME Competencies.
Learning Objectives
At the end of the course, learners should be able to:
- Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
- Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
- Develop practical applications for integrating new and emerging science into practice.
- Identify gaps in the field of addiction medicine that future research can address.
- Create a network of colleagues and resources to support the learner's practice or form future research collaborations.
DEA Education Requirement
As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).
Registration Rates
| ASAM Learner Type | Rate |
| ASAM Member | $29 |
| Non-Member | $39 |
| Associate Member | $19 |
| Resident Member* | $19 |
| Student Member* | $19 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Open: 11/01/2024 - 10/01/2027
User Access Closed: 11/01/2027
Instructions
- Click on the Contents tab to begin this activity.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
George Koob
PhD
George F. Koob, PhD is Director of the National Institute on Alcohol Abuse and Alcoholism where he oversees a wide range of alcohol-related research, including genetics, neuroscience, epidemiology, prevention, and treatment.
As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 750 peer reviewed papers and several books including the “Neurobiology of Addiction,” a comprehensive treatise on emerging research in the field, and a textbook for upper division undergraduates and graduate students called “Drugs, Addiction and the Brain.” He has mentored 12 PhD students, 84 post-doctoral fellows, and 11 K99’s.
He received his PhD in Behavioral Physiology from Johns Hopkins University in 1972. He spent much of his early career at the Scripps Research Institute as the Director of the Alcohol Research Center, and as Professor and Chair of the Scripps’ Committee on the Neurobiology of Addictive Disorders. He has also served as a researcher in the Department of Neurophysiology at the Walter Reed Army Institute of Research and the Arthur Vining Davis Center for Behavioral Neurobiology at the Salk Institute for Biological Studies. Dr. Koob is the recipient of many honors, including membership in the National Academy of Medicine and award of the Legion of Honor (Knight of the Legion of Honor, France).
Wilson Compton
MD, MPE
Wilson M. Compton, MD, MPE serves as the Deputy Director of the National Institute on Drug Abuse (NIDA) of the National Institutes of Health. In his current role, Dr. Compton's responsibilities include providing scientific leadership in the development, implementation, and management of NIDA's research portfolio and working with the Director to support and conduct research to improve the prevention and treatment of drug abuse and addiction. Prior to his current appointment, Dr. Compton served as the Director of NIDA's Division of Epidemiology, Services and Prevention Research from 2002 until 2013. In this leadership role, he oversaw the scientific direction of a complex public health research program of national and international scope addressing: 1) the extent and spread of drug abuse, 2) how to prevention drug abuse, and 3) how to implement drug abuse prevention and treatment services as effectively as possible. Before joining NIDA, Dr. Compton was Associate Professor of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital in Saint Louis. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed his residency training in psychiatry at Washington University. During his career, Dr. Compton has achieved multiple scientific accomplishments: he was selected to serve as a member of the DSM-5 Revision Task Force; is the author of more than 130 articles and chapters; and is an invited speaker at multiple high-impact venues. Dr. Compton is the recipient of multiple awards and in 2008, he received the Senior Scholar Health Services Research Award from the American Psychiatric Association, in 2010 the Paul Hoch Award from the American Psychopathological Association, in both 2012 and 2013, he was selected to receive the Leveraging Collaboration Award from the Food and Drug Administration. In 2013, Dr. Compton received the prestigious Health and Human Services Secretary's Award for Meritorious Service.
Does Disclose: 3M Companies: Ownership Interest includes stock, stock options, patent or other intellectual property; General Electric Co.: Ownership Interest includes stock, stock options, patent or other intellectual property Pfizer, Inc.: Ownership Interest includes stock, stock options, patent or other intellectual property.
Yngvild Olsen
MD, MPH, DFASAM
Dr. Yngvild Olsen serves as the Acting Director for the Center for Substance Abuse Treatment (CSAT). She has a long history of working within the addiction treatment field to expand access to care and enhance quality. She began her career as the Medical Director for the Johns Hopkins Hospital’s outpatient substance use treatment services while a full-time Assistant Professor in the Department of Medicine at the Johns Hopkins School of Medicine. She subsequently served as the Deputy Health Officer for Maryland’s Harford County Health Department. She led a modernization of publicly funded substance use treatment services in collaboration with State and local partners. She next served as the Vice President of Clinical Affairs for the Baltimore Substance Abuse Systems, then the local addiction authority for Baltimore City. In that position, she played a central role in expanding buprenorphine treatment for opioid addiction in both specialty treatment and general ambulatory medical systems. Dr. Olsen has also served as Medical Consultant to the Maryland Behavioral Health Administration, a clinical expert to the Maryland Addiction Consultation Service at the University of Maryland School of Medicine, and an advisor on addiction interventions to the Baltimore City Health Department. From 2011 to 2021, she served as Medical Director for the Institutes for Behavior Resources/REACH Health Services, a comprehensive outpatient substance use disorder treatment program in Baltimore City. She has held numerous senior volunteer leadership positions in the field of addiction medicine, including vice president of the American Society of Addiction Medicine, president of the Maryland Association for the Treatment of Opioid Dependence, and president of the Maryland/DC Society of Addiction Medicine. She also has served on the boards of the National Council on Alcohol and Drug Dependence-Maryland, Stop Stigma Now, and as a clinical expert to the Providers Clinical Support System (PCSS).
Credits & Disclosures
Joint Accreditation Statement
In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available
- Physicians: 1.00 Credit(s)
- Nurses & NPs: 1.00 Nursing Contact Hour(s)
- Pharmacology Hour(s): Not offered
- PAs: 1.00 Credit(s)
- Pharmacists: 1.00 Credit(s)
- Interprofessional Continuing Education: 1.00 Credit(s)
- Certified Counselors: NBCC Contact Hours Not offered
Maintenance of Certification (MOC)/Continuing Certification Program (CCP)
This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.
- ABA MOCA 2.0®*: 1.00 Lifelong Learning
- ABIM MOC Points: 1.00 Medical Knowledge
- ABP MOC: 1.00 Lifelong Learning & Self-Assessment
- ABS Continuing Certification: 1.00 Accredited CME | 1.00 Self-Assessment
Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.
- American Board of Addiction Medicine (ABAM)
- American Board of Preventative Medicine (ABPM)
- American Board of Psychiatry and Neurology (ABPN)
- Royal College of Physicians and Surgeons of Canada (RCPSC)
Certificates for other professions
All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1225.
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205.
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1224.
MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.
Disclosure Information
In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.
See the attached pdf for a list of disclosures.
Key:
Complete
Next
Failed
Available
Locked